Effects of time-dependent administration of antihypertensive treatment in patients with resistant hypertension;Efectos de la administración temporalizada de fármacos antihipertensivos en pacientes con hipertensión arterial resistente

Medicina Clinica

Volumn 126, Issue 10, 2006, Pages 364-372

  Calvo, Carlos ^a   Hermida, Ramon C ^b   Ayala, Diana E ^b   López, José E ^a   Fernández, José R ^b   Mojón, Artemio ^b   Covelo, Manuel ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Chronotherapy; Circadian rhythm; Dipper; Non dipper; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 33646338913     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086047     Document Type: Article

References (54)

1. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-71.
3. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-7.
4. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151:1786-92.
5. Isaksson H, Ostergren J. Prognosis in therapy-resistant hypertension. J Int Med. 1994;236:643-9.
6. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-70.
7. Hernández del Rey R, Armanio P, Martín M, Sánchez P, Cárdenas P, Pardell H. Target organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white coat effect. Blood Press Monit. 1998;3:331-7.
8. Graves JW, Bloomfield RL, Buckalew WM. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med. 1989;298:361-5.
9. Anderson GH, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-15.
10. Myers MG, Reeves RA. White-coat phenomenon in patients receiving antihypertensive therapy. Am J Hypertens. 1991;4:844-9.
11. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucci A, Gioacchino MD, et al. White-coat resistant hypertension. Am J Hypertens. 1997;10:1302-7.
12. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:1263-9.
13. Veglio F, Rabbia F, Riva P, Martini G, Genova GC, Ulan A, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens. 2001;23:203-11.
14. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Pres Monit. 2003;8:181-5.
15. Pickering TG. Blood pressure monitoring outside the office for evaluation of patients with resistant hypertension. Hypertension. 1988;11 Suppl II:96-100.
16. Redón J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712-8.
17. Hermida RC, Calvo C, Ayala DE, Mojón A, Lópz JE. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens. 2002;20:1097-104.
18. Cugini P. The treatability of refractory or resistant hypertension by personalized antihypertensive chronotherapy based on ambulatory monitoring of the arterial pressure. Recenti Prog Med. 1996;87:51-7.
19. Cugini P. Compliance and the chronotherapy of refractory arterial hypertension. Recenti Prog Med. 1997;88:463-9.
20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. Hypertension. 2005;45:142-61.
21. O'Brien E, Staessen J. Normotension and hypertension as defined by 24-hour ambulatory blood pressure monitoring. Blood Press. 1995;4:266-82.
22. O'Brien A, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-48.
23. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003;21:1291-8.
24. Anwar YA, Giacco S, McCabe EJ, Tendler BE, White WB. Evaluation of the efficacy of the Omron HEM-737 Intellisense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit. 1998;3:261-5.
25. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens. 1991;9 Suppl 5:S25-S31.
26. Hermida RC, Fernández JR, Ayala DE, Mojón A, Alonso I, Calvo C. Circadian time-qualified tolerance intervals for ambulatory blood pressure monitoring in the diagnosis of hypertension. Chronobiol Int. 2004;21:149-70.
27. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13:262-7.
28. Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens. 1991;9 Suppl 1:s13-s9.
29. Mojón A, Fernández JR, Hermida RC. Chronolab: An interactive software package for chronobiologic time series analysis written for the Macintosh™ computer. Chronobiol Int. 1992;9:403-12.
30. Fernández JR, Hermida RC. Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol Int. 1998;15:191-204.
31. Fernández JR, Mojón A, Hermida RC. Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol Int. 2004;21:469-84.
32. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
33. Hermida RC, Ayala DE, Calvo C, Domínguez MJ, Covelo M, Mojón A, et al. Ambulatory blood pressure pattern in patients with resistant hypertension as a function of the circadian time of antihypertensive therapy. J Hypertens. 2004;22 Suppl 2:S161.
34. Pickering TG. The clinical significance of diurnal blood pressure variations: dippers and nondippers. Circulation. 1990;81:700-2.
35. Shimada K, Kario K. Altered circadian rhythm of blood pressure and cerebrovascular damage. Blood Press Monit. 1997;2:333-8.
36. Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, et al. «Non-dipper» hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol. 1995;43:382-7.
37. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988;13:397.
38. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
39. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, De Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539-46.
40. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183-9.
41. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension. 2005;45:240-5.
42. Svensson P, De Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension. 2001;38:e28-e32.
43. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96:308-15.
44. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure. A potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983-8.
45. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME. Pulse presure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens. 2001;14:91-7.
46. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation. 2001;103:2579-84.
47. Blacher J, Gasowski J, Staessen JA, Girerd X, This L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160:1085-9.
48. Smolensky MH. Chronobiology and chronotherapeutics: Applications to cardiovascular medicine. En: Deedwania PC, editor. Circadian rhythms of cardiovascular disorders. Armonk: Futura Publishing Co., Inc; 1997. p. 173-206.
49. Lemmer B. Cardiovascular chronobiology and chronopharmacology. Importance of timing of dosing. En: White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press; 2000. p. 255-71.
50. Witte K, Lemmer B. Rhythms and pharmacodynamics. En: Redfern P, editor. Chronotherapeutics. London: Pharmaceutical Press; 2003. p. 111-26.
51. Hermida RC, Smolensky MH. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens. 2004;13:501-5.
52. Portaluppi F, Vergnani L, Manfredini R, Degli Uberti EC, Fersini C. Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure. Am J Hypertens. 1995;8:719-26.
53. Hermida RC, Calvo C, Ayala DE, Covelo M, López JE. Efectos de la administración temporalizada de nifedipino GITS en monoterapia sobre la presion arterial ambulatoria en pacientes con hipertension arterial esencial. Hipertensión Clínica. 2004;5:249.
54. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, et al. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int. 2004;21:469-84.